MedTrace Logo

Impulse Oscillometry in COPD Exacerbation

NCT07185581 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2025-09-22

No results posted yet for this study

Summary

This study aimed to evaluate small airway function during ECOPD and recovery periods using IOS. In this prospective single-center study, patients with ECOPD underwent evaluation of their pulmonary functions using IOS and spirometry during exacerbation and recovery (6-12 weeks after exacerbation). The patients were divided into two groups: mild exacerbations and (moderate and severe) exacerbations based on ROME criteria.A total of 41 patients were initially enrolled, with 38 completing the study. This study reveals that IOS can be easily used in ECOPD, and IOS parameters that reflect small airways (R5-R20, AX, and Fres) are correlated with FEV1% and the severity of dyspnea. Additionally, IOS parameters significantly improve during recovery, except for R20. Further research is necessary on its application in the functional assessment of patients with COPD exacerbations.

Conditions

  • COPD Exacerbation
  • COPD

Interventions

DIAGNOSTIC_TEST

Impulse Oscillometry

Impulse Oscillometry (IOS) is a simple, non-invasive, effort-independent method that uses sound waves to detect airway changes quickly. It only requires the patient to breathe normally to assess lung function by measuring both resistance and reactance of the airways. 6,7 These features of IOS suggest it may be a useful test for assessing patient respiratory function during exacerbation periods when airway resistance, airflow limitation, and respiratory muscle weakness further impair breathing.

Sponsors & Collaborators

  • Deniz Bilici

    lead OTHER

Principal Investigators

  • Esma Seda Akalın, MD · Istanbul Medeniyet University

  • Deniz Koçak, Research Assistant · Istanbul Medeniyet University

  • Elif Hazal Karadağ, Research Assistant · Istanbul Medeniyet University

  • Burcu Arpınar Yiğitbaş, Associate professor: · Istanbul Medeniyet University

  • Deniz Bilici, MD · Istanbul Medeniyet University

  • Handan Ankaralı, Professor · Istanbul Medeniyet University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185581 on ClinicalTrials.gov